| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/03/2003 | WO2002080914A3 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments |
| 01/03/2003 | WO2002076484A3 Combination of a taxane and a cyclin-dependent kinase inhibitor |
| 01/03/2003 | WO2002072584A3 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 01/03/2003 | WO2002072029A3 Dopamine d4 receptor antagonists as treatment for attention deficit-hyperactivity disorder |
| 01/03/2003 | WO2002070069A3 Use of one or more shogaol(s) as an aphrodisiac |
| 01/03/2003 | WO2002069960A3 Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| 01/03/2003 | WO2002066489A3 Amphoteric sterols and the use thereof in the production of ph-sensitive liposomes |
| 01/03/2003 | WO2002066020A3 Modulation of gsk-3beta activity and its different uses |
| 01/03/2003 | WO2002060911A3 C-glucosyl ether lipids |
| 01/03/2003 | WO2002060870A3 Delta agonist analgesics |
| 01/03/2003 | WO2002060869A3 Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
| 01/03/2003 | WO2002058682A3 An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation |
| 01/03/2003 | WO2002056915A3 Complex of modafinil and cyclodextrin |
| 01/03/2003 | WO2002051828A3 Novel c-glycoside derivatives and use thereof |
| 01/03/2003 | WO2002048166A8 Indolocarbazole anticancer agents and methods of using them |
| 01/03/2003 | WO2002047673A3 Methods and compositions to treat conditions associated with neovascularization |
| 01/03/2003 | WO2002046170A8 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 01/03/2003 | WO2002045702A3 Tricyclic therapeutics for chemokine mediated diseases |
| 01/03/2003 | WO2002044366A3 Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 |
| 01/03/2003 | WO2002043653A3 Crystalline glucosamine sulphate metal salts |
| 01/03/2003 | WO2002040058A3 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
| 01/03/2003 | WO2002034741A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 01/03/2003 | WO2002032918A3 Ketolide antibacterials |
| 01/03/2003 | WO2002030399A3 Polymer controlled delivery of a therapeutic agent |
| 01/03/2003 | WO2002026757A3 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 01/03/2003 | WO2002009761A3 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 01/03/2003 | WO2002009715A3 Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer |
| 01/03/2003 | WO2002009699A3 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 01/03/2003 | WO2002008187A9 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/03/2003 | WO2002005842A3 Preventing airway mucus production by administration of egf-r antagonists |
| 01/03/2003 | WO2002005791A3 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
| 01/03/2003 | WO2002004452A3 Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| 01/03/2003 | WO2002004451A3 Methods for stimulation of synthesis of synaptophysin in the central nervous system |
| 01/03/2003 | WO2002003976A3 Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| 01/03/2003 | WO2002002563A3 Substituted-triazolopyrimidines as anticancer agents |
| 01/03/2003 | WO2002002131A3 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/03/2003 | WO2002002087A2 Anthelminthic agents for the prevention of parasitic infections in humans and animals ii |
| 01/03/2003 | WO2002002086A1 Dermal therapeutic system containing 2-(3-benzophenyl)-propionic acid or '0-(2,6-dichloranilino)-phenyl!-ethanoic acid |
| 01/03/2003 | WO2001089502A3 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 01/03/2003 | WO2001064899A8 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method |
| 01/03/2003 | WO2001044260A8 Novel purines |
| 01/03/2003 | CA2790034A1 Antisense modulation of superoxide dismutase 1, soluble expression |
| 01/03/2003 | CA2677781A1 Nitrilases |
| 01/03/2003 | CA2633595A1 Antibodies against tumor-associated antigenic target (tat) polypeptides |
| 01/03/2003 | CA2489623A1 Atopy |
| 01/03/2003 | CA2459985A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2455288A1 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/03/2003 | CA2454538A1 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| 01/03/2003 | CA2452088A1 Compositions and methods for intracellular delivery |
| 01/03/2003 | CA2452049A1 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 01/03/2003 | CA2451974A1 Chimeric immunomodulatory compounds and methods of using the same |
| 01/03/2003 | CA2451885A1 Method and material for treating immune diseases |
| 01/03/2003 | CA2451841A1 Method for enhancing the effectiveness of cancer therapies |
| 01/03/2003 | CA2451839A1 Pharmaceutical compositions comprising peptides and permeation enhancers |
| 01/03/2003 | CA2451745A1 .beta.-2'-or 3'-halonucleosides |
| 01/03/2003 | CA2451686A1 A novel g protein-coupled receptor, gave 3 |
| 01/03/2003 | CA2451664A1 Use of bicyclo compounds for treating alzheimer's disease |
| 01/03/2003 | CA2451625A1 Substituted n-acyl-aniline derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 01/03/2003 | CA2451602A1 Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease |
| 01/03/2003 | CA2451543A1 Thiazolyl amides and their use as antiviral drugs |
| 01/03/2003 | CA2451525A1 Imidazotriazines for use as phosphodiesterase inhibitors |
| 01/03/2003 | CA2451311A1 Stimulation of vascularization with vegf-b |
| 01/03/2003 | CA2451271A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451249A1 Amino nicotinate derivatives as glucokinase (glk) modulators |
| 01/03/2003 | CA2451248A1 Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 01/03/2003 | CA2451247A1 Eukaryotic genes involved in adult lifespan regulation |
| 01/03/2003 | CA2451245A1 Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| 01/03/2003 | CA2451161A1 Method for high through put screening using a small scale mill or microfluidics |
| 01/03/2003 | CA2451152A1 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| 01/03/2003 | CA2451146A1 Method for manufacturing of free-flowing powder containing water-dispersible sterols |
| 01/03/2003 | CA2451008A1 Imidazo¬1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
| 01/03/2003 | CA2450957A1 Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| 01/03/2003 | CA2450954A1 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | CA2450947A1 Black soybean polysaccharides |
| 01/03/2003 | CA2450942A1 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 01/03/2003 | CA2450762A1 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| 01/03/2003 | CA2450758A1 Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases |
| 01/03/2003 | CA2450748A1 Pharmaceutical compositions containing polymer and drug assemblies |
| 01/03/2003 | CA2450742A1 Pediatric formulation of gatifloxacin |
| 01/03/2003 | CA2450583A1 Antihistamines for the treatment of nasal congestion and nasal obstruction |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450555A1 (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| 01/03/2003 | CA2450550A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450480A1 Oxytocin agonists |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450449A1 Pharmaceutical formulation |
| 01/03/2003 | CA2450174A1 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 01/03/2003 | CA2450002A1 Benzenesulfonyl(thio)ureas for the treatment of septic shock and sirs |
| 01/03/2003 | CA2450001A1 Stable pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449998A1 Stable controlled release pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | CA2449441A1 3-fluoro-pyrrolidines as antidiabetic agents |
| 01/03/2003 | CA2449439A1 Particles for inhalation having rapid release properties |
| 01/03/2003 | CA2414274A1 Vehicle used to apply chemical compounds to wood |
| 01/03/2003 | CA2413581A1 Anthelminthic agents for the prevention of parasitic infections in humans and animals ii |
| 01/02/2003 | WO2002002529A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |